[Market Movers Analysis] MedicusPharma surges on September 17: Pfizer ADC collaboration and SkinJect

1. On September 2, the company entered into a joint development and licensing agreement with Pfizer for the CD228V antibody-drug conjugate, with potential development, regulatory, and sales milestone payments exceeding $1 billion; Pfizer is also providing approximately $2 million in development funding, inventory, and infrastructure support.
2. On September 10, the company announced the results of the Phase II SKNJCT-003 SkinJect® study— all 90 patients completed the trial, and the 200-microgram patch was determined as the primary dosage for further development; relevant data will be used to advance the FDA-authorized SKNJCT-005 study for Gorlin syndrome.

(Disclaimer: This content is collected and summarized from public information by AI technology for reference only and does not constitute investment advice.)